Apnimed (APMD) vs Gyre Therapeutics (GYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Apnimed is the larger company by market cap ($771.0 million vs $746.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APMD | GYRE |
|---|---|---|
| Share price | $18.52 | $7.04 |
| Market cap | $771.00M | $746.48M |
| 1-day change | +1.65% | +4.14% |
| YTD return | — | -4.25% |
| 1-year return | — | -7.40% |
| 5-year return | — | -88.73% |
| P/E ratio (TTM) | 2.57 | — |
| Forward P/E | — | 117.33 |
| EPS (TTM) | $7.22 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.29 | $9.42 |
| 52-week low | $16.12 | $5.44 |
| Distance from 52-week high | -47.52% | -25.27% |
| Analyst consensus | none | none |
| Avg. price target upside | +171.76% | +165.20% |
| Average volume | 552.07K | 105.93K |
| Shares outstanding | 41.63M | 106.03M |
| Employees | 81 | 625 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apnimed
APMD stock →Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
APMD vs GYRE FAQ
Which is bigger, Apnimed or Gyre Therapeutics?
Apnimed (APMD) is larger, with a market capitalization of $771.00M compared with $746.48M for Gyre Therapeutics (GYRE).
Are Apnimed and Gyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.